

Matthias Klinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1181592/publications.pdf>

Version: 2024-02-01

13
papers

3,364
citations

840776

11
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

3304
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody. <i>Science</i> , 2008, 321, 974-977.	12.6	957
2	Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival. <i>Journal of Clinical Oncology</i> , 2011, 29, 2493-2498.	1.6	819
3	Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. <i>Blood</i> , 2012, 120, 5185-5187.	1.4	435
4	Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. <i>Blood</i> , 2012, 119, 6226-6233.	1.4	410
5	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1104-1111.	1.6	359
6	Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. <i>Blood</i> , 2015, 126, 2578-2584.	1.4	136
7	Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. <i>Haematologica</i> , 2017, 102, e132-e135.	3.5	81
8	Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. <i>Experimental Hematology and Oncology</i> , 2017, 6, 14.	5.0	60
9	Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events. <i>Cancer Research</i> , 2020, 80, 91-101.	0.9	54
10	Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. <i>Annual Review of Cancer Biology</i> , 2022, 6, 17-34.	4.5	23
11	Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma. <i>Current Clinical Pharmacology</i> , 2018, 13, 55-64.	0.6	19
12	CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29323.	1.5	8
13	Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab. <i>Experimental Hematology</i> , 2021, 100, 32-36.	0.4	3